Collaborative drug therapy management and comprehensive medication management-2015

Area of Science:

• Health Policy
• Pharmacoeconomics
• Clinical Pharmacy Practice

Background:

• The American College of Clinical Pharmacy (ACCP) has updated its stance on collaborative drug therapy management (CDTM) due to evolving legislation since 2003.
• Current healthcare trends emphasize patient-centered, team-based care, linking payment to outcomes.

Purpose of the Study:

• To highlight the role of clinical pharmacists in delivering comprehensive medication management (CMM) through CDTM.
• To address barriers limiting patient access to CMM, particularly payer recognition and reimbursement policies.

Main Methods:

• Review of legislative changes and ACCP position statements on CDTM.
• Analysis of the integration of CMM within team-based care models.
• Examination of economic value and access barriers for clinical pharmacists in collaborative settings.

Main Results:

• CDTM is a suitable framework for clinical pharmacists to provide CMM, optimizing medication-related outcomes.
• The economic value of clinical pharmacists in team-based care is established.
• Patient access to CMM is constrained by limited payer recognition and inadequate healthcare payment policies.

Conclusions:

• Clinical pharmacists are well-positioned to provide CMM via CDTM and other collaborative mechanisms.
• Continued expansion of CDTM is necessary to enhance recognition of clinical pharmacists' impact on medication outcomes.
• Addressing payer recognition and payment policies is essential for broader patient access to CMM.